Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- December15 2004
- Volume 11
- Issue 23
Discount Broker Battles
Author(s)Michael Sheehan
Advertisement
A drop in online trading from 7.2%of American households in 2000 to5.9% this year is causing headaches fordiscount stockbrokers looking to shoreup faltering revenues. As online tradingvolume wanes, brokers are fighting formarket share. Some, like CharlesSchwab and E*Trade, are rolling outcredit cards that award points that canbe used for free stock trades. For now,however, the most popular businessretention tool is a deeper discount foractive traders. For example, if youmake 27 trades or more in a quarter,you can cut the commission at E*Tradefrom $19.99 plus a $3 handling fee pertrade to just $9.99. Over at FidelityInvestments, $30,000 and 120 trades ayear will get you an $8 per-trade commissioninstead of the usual $19.95.
Articles in this issue
about 18 years ago
Steer Clear of Dangerous Tax Promisesabout 18 years ago
Tactfully Time Your Disability Insuranceabout 18 years ago
Safeguard Your Assets with a Solid Wealth Preservation Planabout 18 years ago
Expose Your Portfolio to Foreign Dineroabout 18 years ago
Minimize Irrational Investing Behaviorabout 18 years ago
Model Portfolio Series: Equity Incomeabout 18 years ago
SUV Loophole Tighteningabout 18 years ago
Going DIY on Financesabout 18 years ago
The State of Death Taxesabout 18 years ago
Cost of a WillAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5